Search Result

Results for "

multitarget

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (1) Akt (1) Amyloid-β (4) Apoptosis (5) Aurora Kinase (1) Autophagy (15) Bacterial (2) Bcr-Abl (1) Beta-secretase (3) c-Fms (7) c-Kit (13) c-Met/HGFR (1) Cannabinoid Receptor (1) Cathepsin (1) CDK (3) CDKL (1) Cholinesterase (ChE) (15) COX (4) Dihydroorotate Dehydrogenase (1) Dopamine Receptor (3) Drug Derivative (1) Drug Metabolite (6) DYRK (1) EGFR (6) Endogenous Metabolite (8) FAAH (4) FGFR (11) FLT3 (3) Glucocorticoid Receptor (2) GSK-3 (2) HDAC (4) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) HSP (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) IRAK (1) Isotope-Labeled Compounds (4) JAK (1) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (1) MMP (2) Monoamine Oxidase (10) NF-κB (2) NO Synthase (2) Opioid Receptor (1) p38 MAPK (3) PARP (1) PDGFR (17) Phospholipase (1) Pim (1) Polo-like Kinase (PLK) (1) PPAR (1) Raf (3) Ras (1) Reactive Oxygen Species (1) RET (3) RIP kinase (1) ROCK (1) SARS-CoV (1) Src (3) Tau Protein (1) Thymidylate Synthase (1) Topoisomerase (2) Trk Receptor (1) VEGFR (20) Virus Protease (1) VKOR (2) β-catenin (1) γ-secretase (1)
By Research Areas:	Cancer (40) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (28)

By Targets:

5-HT Receptor (4)

Adrenergic Receptor (1)

Akt (1)

Amyloid-β (4)

Apoptosis (5)

Aurora Kinase (1)

Autophagy (15)

Bacterial (2)

Bcr-Abl (1)

Beta-secretase (3)

c-Fms (7)

c-Kit (13)

c-Met/HGFR (1)

Cannabinoid Receptor (1)

Cathepsin (1)

CDK (3)

CDKL (1)

Cholinesterase (ChE) (15)

COX (4)

Dihydroorotate Dehydrogenase (1)

Dopamine Receptor (3)

Drug Derivative (1)

Drug Metabolite (6)

DYRK (1)

EGFR (6)

Endogenous Metabolite (8)

FAAH (4)

FGFR (11)

FLT3 (3)

Glucocorticoid Receptor (2)

GSK-3 (2)

HDAC (4)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (1)

HSP (1)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

IRAK (1)

Isotope-Labeled Compounds (4)

JAK (1)

JNK (1)

Keap1-Nrf2 (1)

MDM-2/p53 (1)

MMP (2)

Monoamine Oxidase (10)

NF-κB (2)

NO Synthase (2)

Opioid Receptor (1)

p38 MAPK (3)

PARP (1)

PDGFR (17)

Phospholipase (1)

Pim (1)

Polo-like Kinase (PLK) (1)

PPAR (1)

Raf (3)

Ras (1)

Reactive Oxygen Species (1)

RET (3)

RIP kinase (1)

ROCK (1)

SARS-CoV (1)

Src (3)

Tau Protein (1)

Thymidylate Synthase (1)

Topoisomerase (2)

Trk Receptor (1)

VEGFR (20)

Virus Protease (1)

VKOR (2)

β-catenin (1)

γ-secretase (1)

By Research Areas:

Cancer (40)

Cardiovascular Disease (2)

Infection (3)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (28)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149636

Multi-target kinase inhibitor 2	EGFR CDK VEGFR	Cancer
Multi-target kinase inhibitor 2 (compound 5K) is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC₅₀ values ranging from 40 to 204 nM. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC₅₀ of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells.

HY-10338

Foretinib 10+ Cited Publications XL880; GSK1363089; GSK089; EXEL-2880	VEGFR c-Met/HGFR	Cancer
Foretinib is a multi-target tyrosine kinase inhibitor with IC₅₀s of 0.4 nM and 0.9 nM for Met and KDR.

HY-169216

Multi-target kinase inhibitor 3	Others	Cancer
Multi-target kinase inhibitor 3 (compund 6i) is a potent multi-target anticancer agent .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

HY-162092

Multi-target Pt	NF-κB IKK	Cancer
Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .

HY-158978

Multitarget AD inhibitor-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC₅₀=0.14 μM), butyrylcholinesterase (BChE, IC₅₀=11.6 μM), monoamine oxidase B (MAO B, IC₅₀=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .

HY-145294

ROCK2-IN-5	ROCK	Neurological Disease
ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-155378

PZ-1190	5-HT Receptor Dopamine Receptor	Neurological Disease
PZ-1190 is a multitarget ligand for serotonin and dopamine receptors with potential antipsychotic activity in rodents .

HY-172176

RA-PR058	Beta-secretase Tau Protein	Neurological Disease
RA-PR058 is an orally active Ramalin derivative with blood-brain barrier permeability, exhibiting multi-target regulatory effects and favorable pharmacokinetic properties. RA-PR058 demonstrates potential as a multi-target modulator for Alzheimer's disease by reducing the expression of BACE1, tau protein hyperphosphorylation, and anxiety-like behaviors .

HY-G0017A

N-Desmethyl imatinib mesylate Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate	Drug Metabolite	Others
N-Desmethyl imatinib mesylate (Norimatinib mesylate) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-G0017

N-Desmethyl imatinib 1 Publications Verification Norimatinib; Imatinib metabolite N-Desmethyl imatinib	Drug Metabolite	Others
N-Desmethyl imatinib (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-10644

Lck inhibitor 2	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-167869

A-849529	Drug Metabolite	Others
A-849529 is an acid metabolite of ABT-869 (HY-50751). ABT-869 is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family .

HY-139680

Dopamine D3 receptor antagonist-1	Dopamine Receptor	Neurological Disease
Dopamine D3 receptor antagonist-1 is a dopamine D₃ receptor-selective or multitarget bitopic ligand (K_i = 1.58 nM) potentially useful for central nervous system disorders.

HY-139681

Dopamine D3 receptor antagonist-2	Dopamine Receptor	Neurological Disease
Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective (K_i = 2.16 nM) or multitarget bitopic ligand potentially useful for central nervous system disorders.

HY-120520

Caylin-1	MDM-2/p53	Cancer
Caylin-1 is an inhibitor of MDM2 and an analog of Nutlin-3. Caylin-1 can bind to Bcl-XL and is used in multi-target anticancer research .

HY-W591818

Sunitinib carboxylic acid	Drug Derivative	Cancer
Sunitinib carboxylic acid is a carboxylic acid metabolite of Sunitinib (HY-10255A). Sunitinib is a multi-target tyrosine kinase inhibitor, mainly used to inhibit malignant tumors such as gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors .

HY-12009

Pazopanib Hydrochloride 15+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-155546

Antimicrobial agent-22	Bacterial	Infection
Antimicrobial agent-22 (THI 6c) is a multi-target broad-spectrum antibacterial agent. Antimicrobial agent-22 has low cytotoxicity, hemolytic property, rapid bactericidal ability and good anti-biofilm activity .

HY-B1227

Carprofen 2 Publications Verification	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-158310

SOS1/EGFR-IN-1	EGFR Ras	Cancer
SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC₅₀=42.13±1.55 nM) and EGFR(IC₅₀=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC₅₀=0.45±0.03 μM) .

HY-158695

Dual AChE-MAO B-IN-4	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-4 (compound 7) is a dual AChE/MAO-B inhibitor, with IC₅₀ values of 261 nM and 15 nM, respectively. Dual AChE-MAO B-IN-4 protects against oxidative damage induced by H₂O₂ and 6-OHDA in SH-SY5Y cells. Dual AChE-MAO B-IN-4 can penetrate the central nervous system in a cell model that mimics the blood-brain barrier. Dual AChE-MAO B-IN-4 can be used in the study of neurological diseases such as Alzheimer's disease (AD) .

HY-158696

BChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
BChE/MAO-B-IN-1 (compound 7) is a dual BChE/MAO-B inhibitor with IC₅₀ values of 375 nM and 20 nM, respectively. BChE/MAO-B-IN-1 protects against oxidative damage induced by H₂O₂ and 6-OHDA in SH-SY5Y cells. BChE/MAO-B-IN-1 can penetrate the central nervous system in a cell model that mimics the blood-brain barrier. BChE/MAO-B-IN-1 can be used in the study of neurological diseases such as Alzheimer's disease (AD) .

HY-10208

Pazopanib 15+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-100315

XL 999 Tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease Cancer
XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC₅₀ values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer .

HY-13308

Regorafenib Hydrochloride Maximum Cited Publications 65 Publications Verification BAY 73-4506 hydrochloride	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

HY-128346

PQM130	Amyloid-β	Neurological Disease
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget agent candidate against the neurotoxicity induced by Aβ_1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD agent development .

HY-158334

NDs-IN-1	Cholinesterase (ChE) Monoamine Oxidase NO Synthase PARP p38 MAPK RIP kinase Phospholipase Indoleamine 2,3-Dioxygenase (IDO) Dihydroorotate Dehydrogenase	Neurological Disease
(Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases .

HY-132166

M4205 IDRX-42	c-Kit PDGFR c-Fms FLT3 Src	Cancer
M4205 is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC₅₀s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. M4205 exhibits antitumor efficacy in xenograft mouse models .

HY-161244

FGA145	SARS-CoV Cathepsin Virus Protease	Infection
FGA145 is a dual, selective inhibitor for M ^pro and human Cathepsin L, with K_is of 3.71 μM, 9.82 μM and 53 nM, for Mal-M ^pro, pET21-M ^pro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity .

HY-G0017S1

N-Desmethyl imatinib-d4 Norimatinib-d₄; Imatinib metabolite N-Desmethyl imatinib-d₄	Isotope-Labeled Compounds	Others
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-B1227S

Carprofen-d3	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N10429

Geissoschizoline (+)-Geissoschizoline	Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human AChE/BChE, with IC₅₀s of 20.40 µM and 10.21 µM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent .

HY-I0678

Regorafénib N-oxyde (M2)	Drug Metabolite PDGFR	Cancer
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-10208S

Pazopanib-d6 GW786034-d₆	Isotope-Labeled Compounds VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-143499

hMAO-B-IN-3	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-3 (Compound 15) is a potent inhibitor of hMAO-B with an IC₅₀ of 47.4 nM. hMAO-B-IN-3 is playing favourable agent-like properties and a broad safety window. hMAO-B-IN-3 is thus a suitable candidate for lead optimization and the development of multitarget-directed ligands .

HY-B1227R

Carprofen (Standard)	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-W011873R

Palmitoleic acid (Standard)	Endogenous Metabolite	Neurological Disease
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-163885

SSZ	Cholinesterase (ChE) Beta-secretase γ-secretase	Neurological Disease
SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .

HY-12009R

Pazopanib (Hydrochloride) (Standard)	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-155377

PLK1/p38γ-IN-1	Polo-like Kinase (PLK) p38 MAPK	Cancer
PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro .

HY-111186

Flocoumafen WL 108366	Glucocorticoid Receptor MMP VKOR	Others
Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .

HY-10208R

Pazopanib (Standard)	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (Standard) is the analytical standard of Pazopanib. This product is intended for research and analytical applications. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-128872

Etrinabdione EHP-101; VCE-004.8	PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB₂ receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity .

HY-121974

SR14150	Opioid Receptor	Neurological Disease
SR14150 is a partial agonist of the NOP receptor with high affinity. The biological activity of SR14150 makes it potentially useful for the development of a new generation of multi-target opioids designed to simultaneously improve analgesia and reduce side effects. The activity of SR14150 and its interaction with other opioid receptors may provide new inhibitory options for the management of chronic pain .

HY-172198

GSK3-IN-10	GSK-3 β-catenin DYRK JNK CDK CDKL	Neurological Disease
GSK3-IN-10 (Compound 4) is a multi-target inhibitor, that mainly targets GSK3α and GSK3β with IC₅₀ of 1.0 nM and 2.0 nM. GSK3-IN-10 inhibits the activation of β-catenin, promotes the neuronal survival, and exhibits a protective effect against endoplasmic reticulum stress .

HY-W705479

Pazopanib-d3 hydrochloride GW786034-d₃ hydrochloride	Isotope-Labeled Compounds Autophagy PDGFR FGFR c-Fms VEGFR c-Kit	Cancer
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S2

Pazopanib-d3 GW786034-d₃	Isotope-Labeled Compounds Autophagy VEGFR c-Kit PDGFR FGFR	Cancer
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC₅₀=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .

Cat. No.	Product Name

HY-L176

Multi-Target Compound Library

5,069 compounds

The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies.

MCE supplies a unique collection of 5,069 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.

HY-L065

Traditional Chinese Medicine Active Compound Library

2,953 compounds

Chinese herbal therapy is an important part of Traditional Chinese Medicine (TCM). It has been used for centuries in China, where herbs are considered fundamental therapy for many acute and chronic conditions. Many studies indicated TCM exerted an overall regulatory effect via multi-component and multi-target network. Active components from Traditional Chinese Medicine possess many medicinal properties such as antioxidant, anti-cancer, and anti-bacterial effects, which makes it an important source of new drugs. Nearly 200 modern medicines have been developed either directly or indirectly from the plants used as medicines in China. For example, artemisinin, used in multidrug resistant malaria, was first isolated from the Chinese herb Artemisia annua L. Today, scientists continue to identify compounds in Chinese herbal remedies that may be useful in the development of new therapeutic agents applicable in Western medicine.

MCE designs a unique collection of 2,953 active compounds of Chinese Herbal Medicines. MCE Traditional Chinese Medicine Active Compound Library is a useful tool for discovery new drugs from TCM.

Cat. No.	Product Name	Type

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Fluorescent Dye

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

Cat. No.	Product Name	Type

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), HDAC3 (IC₅₀=9.18 nM), HDAC6 (IC₅₀=42.7 nM), HDAC8 (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1227

Carprofen 2 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	COX FAAH Autophagy Endogenous Metabolite
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-B1227R

Carprofen (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	COX FAAH Autophagy Endogenous Metabolite
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N10429

Geissoschizoline (+)-Geissoschizoline	Alkaloids other families Pyrrole Alkaloids Classification of Application Fields Neurological Disease Source classification Pteris wallichiana Agardh Plants Disease Research Fields Inflammation/Immunology Indole Alkaloids	Cholinesterase (ChE)
Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human AChE/BChE, with IC₅₀s of 20.40 µM and 10.21 µM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent .

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-G0017S1

N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-B1227S

Carprofen-d3
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-B1227S1

Carprofen-13C,d3
Carprofen- ¹³C,d₃ is the deuterium and ¹³C labeled Carprofen[1]. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively[2][3][4].

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

multitarget

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products